Baxdela is intended to treat skin and skin structure infections caused by various gram-positive and gram-negative bacteria, including methicillin-resistant Staphylococcus aureus. The antibiotic is available in intravenous and oral form.
“Antibiotic resistance is a growing concern, and physicians need more tools in the fight against this threat to modern medicine,” said David Hooper, MD, professor of medicine at Cambridge, Mass.-based Harvard University and infection control leader at Massachusetts General Hospital in Boston. “Approval of new therapies like Baxdela … provides physicians another option in addressing the challenges of [acute bacterial skin and skin structure infections] patients.”
More articles on supply chain:
25 top supply chains in 2017, as ranked by Gartner
Baltimore’s naloxone supply dwindling as opioid overdose rates surge
Patients seeking financial assistance for $750k Biogen drug must sign away PHI
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
